PRECLINICAL VALIDATION OF NOVEL FLUORESCENTLY LABELED COMPOUNTS TO TREAT NEURODEGENERATIVE HEARING LOSS

$1,500,000FY2015Department of DefenseDOD

Massachusetts Eye And Ear Infirmary, Boston MA

Investigators